Evidence map›Paper›PMID 40644310›Full record

ArticleMolecular oncology2025

Endoglin mediates the tumor- and metastasis-promoting traits of stromal myofibroblasts in human breast carcinomas.

Shoki Okubo, Yoshihiro Mezawa, Zixu Wang, Ahmet Acar, Yasuhiko Ito, Atsushi Takano, Yohei Miyagi, Tomoyuki Yokose, Toshinari Yamashita, Yataro Daigo and 2 more

Abstract read
In one paragraph

Article in Molecular oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Shoki OkuboDepartment of Gastroenterology, Graduate School of Medicine, Juntendo University, Tokyo, Japan.ORCID 0000-0001-5319-8717
Yoshihiro MezawaDepartment of Molecular Pathogenesis, Graduate School of Medicine, Juntendo University, Tokyo, Japan.ORCID 0000-0002-2095-3867
Zixu WangDepartment of Molecular Pathogenesis, Graduate School of Medicine, Juntendo University, Tokyo, Japan.
Ahmet AcarDepartment of Biological Sciences, Middle East Technical University, Ankara, Turkey.ORCID 0000-0002-2478-8029
Yasuhiko ItoDepartment of Molecular Pathogenesis, Graduate School of Medicine, Juntendo University, Tokyo, Japan.
Atsushi TakanoCenter for Antibody and Vaccine Therapy, Institute of Medical Science, Research Hospital, The University of Tokyo, Japan.
Yohei MiyagiMolecular Pathology and Genetics Division, Kanagawa Cancer Center Research Institute, Yokohama, Japan.
Tomoyuki YokoseDepartment of Pathology, Kanagawa Cancer Center, Yokohama, Japan.
Toshinari YamashitaDepartment of Breast and Endocrine Surgery, Kanagawa Cancer Center, Yokohama, Japan.
Yataro DaigoCenter for Antibody and Vaccine Therapy, Institute of Medical Science, Research Hospital, The University of Tokyo, Japan.
Takuya ShirakiharaDepartment of Molecular Pathogenesis, Graduate School of Medicine, Juntendo University, Tokyo, Japan.ORCID 0000-0002-6222-0143
Akira OrimoDepartment of Molecular Pathogenesis, Graduate School of Medicine, Juntendo University, Tokyo, Japan.ORCID 0000-0001-5330-7282

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Carcinoma-associated fibroblasts (CAFs), which are abundant in the tumor microenvironment, influence cancer hallmarks. We previously described transforming growth factor-β (TGF-β)-Smad2/3 signaling as being activated in myofibroblastic CAFs (myCAFs) in an autocrine fashion by increasing TGF-β production. However, factors regulating such autocrine TGF-β signaling remain poorly understood. Herein, we show that the abundance of endoglin (ENG), a TGF-β superfamily coreceptor expressed on human breast myCAFs, is significantly associated with poorer outcomes of breast cancer patients. Inhibition of ENG expression on myCAFs not only suppressed the TGF-β-Smad2/3 pathway and TGF-β1 expression but also attenuated the ability of myCAF to promote primary tumor growth and metastasis. Mechanistically, ENG facilitates TGF-β-Smad2/3 signaling in myCAFs, presumably through association with a TGF-β ligand-receptor complex, leading to self-stimulating TGF-β1 production. Stromal TGF-β1, in turn, induces partial epithelial-mesenchymal transition in cancer cells in a paracrine manner, resulting in suppression of primary tumor growth and promotion of invasion and metastasis. ENG-primed TGF-β autocrine signaling also produces other factors that could mediate primary tumor growth promotion by myCAFs. Collectively, these findings suggest that ENG-primed TGF-β autocrine and paracrine signaling mediates tumor- and metastasis-promoting abilities of myCAFs.

Indexed as

Breast NeoplasmsEndoglinMyofibroblastsAnimalsCancer-Associated FibroblastsCell Line, TumorEpithelial-Mesenchymal TransitionFemaleHumansMiceNeoplasm MetastasisSignal TransductionSmad2 ProteinSmad3 ProteinTransforming Growth Factor betaTransforming Growth Factor beta1EndoglinENG protein, humanSmad2 ProteinSmad3 ProteinTransforming Growth Factor betaTransforming Growth Factor beta1breast cancerendoglinmyofibroblastic carcinoma‐associated fibroblastsTGF‐β1TGF‐β‐Smad2/3 signalingtumor microenvironment

Identifiers

PMID40644310
PMCPMC12420333

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.